TCR_Public/131228.mbx          T R O U B L E D   C O M P A N Y   R E P O R T E R

           Saturday, December 28, 2013, Vol. 17, No. 358


EXIDE TECHNOLOGY: Net Loss Grows in November to $16.7 Million
FAIRMONT GENERAL: Lists $837,610 Cash Profit in September
FAIRMONT GENERAL: Reports $125,047 Net Income for October
SAVIENT PHARMACEUTICALS: Incurs $2.92-Mil. Net Loss in November


EXIDE TECHNOLOGY: Net Loss Grows in November to $16.7 Million
Bill Rochelle, the bankruptcy columnist for Bloomberg News,
reports that battery maker Exide Technologies reported a net loss
of $16.7 million in November, larger that the October loss of
$12.1 million.

According to the report, the operating report filed with the U.S.
Bankruptcy Court in Delaware shows November revenue of $86.1
million, an $11 million decline from the prior month. The
operating loss in November was $1 million, five times higher than

From inception of the Chapter 11 reorganization in June, the
cumulative net loss is $92 million on revenue of $539.7 million.
Total Chapter 11 costs so far are $42.8 million.

The $674 million of 8.625 percent first-lien notes due 2018 traded
at 2:35 p.m. on Dec. 20 for 72 cents on the dollar, according to
Trace, the bond-price reporting system of the Financial Industry
Regulatory Authority. The bonds are up 27 percent since the last
trade before bankruptcy at 56.672 cents.  The convertible
subordinated notes due in September traded at 11:56 a.m. on Dec.
20 for 22.25 cents on the dollar, compared with 10.5 cents in the
last trade before bankruptcy.

                  About Exide Technologies

Headquartered in Princeton, New Jersey, Exide Technologies
(NASDAQ: XIDE) -- manufactures and
distributes lead acid batteries and other related electrical
energy storage products.

Exide first sought Chapter 11 protection (Bankr. Del. Case No.
02-11125) on April 14, 2002 and exited bankruptcy two years after.
Matthew N. Kleiman, Esq., and Kirk A. Kennedy, Esq., at Kirkland &
Ellis, and James E. O'Neill, Esq., at Pachulski Stang Ziehl &
Jones LLP represented the Debtors in their successful

Exide returned to Chapter 11 bankruptcy (Bankr. D. Del. Case No.
13-11482) on June 10, 2013.

For the new case, Exide has tapped Anthony W. Clark, Esq., at
Skadden, Arps, Slate, Meagher & Flom LLP, and Pachulski Stang
Ziehl & Jones LLP as counsel; Alvarez & Marsal as financial
advisor; Sitrick and Company Inc. as public relations consultant
and GCG as claims agent.

The Debtor disclosed $1.89 billion in assets and $1.14 billion in
liabilities as of March 31, 2013.

Exide's international operations were not included in the filing
and will continue their business operations without supervision
from the U.S. courts.

The Official Committee of Unsecured Creditors is represented by
Lowenstein Sandler LLP and Morris, Nichols, Arsht & Tunnell LLP as
co counsel.  Zolfo Cooper, LLC serves as its bankruptcy
consultants and financial advisors.

FAIRMONT GENERAL: Lists $837,610 Cash Profit in September
Fairmont General Hospital, Inc., and its subsidiaries, on Nov. 22,
2013, filed their monthly operating report for September 2013.

For the reporting period, the Debtors listed a $837,610 cash

The Debtors also listed $5.4 million in total income and $4.80
million in total expenses for the month.

A copy of the September monthly operating report is available at:

FAIRMONT GENERAL: Reports $125,047 Net Income for October
Fairmont General Hospital, Inc., and its subsidiaries, on Nov. 22,
2013, filed their monthly operating report for October 2013.

Fairmont General's October consolidated statement of operations
showed a net income from operations of $125,047 on total revenues
of $7.57 million.

At October 31, the Debtors reported total assets of $49.74
million, total liabilities of $41.48 million, and a $8.26 million
total shareholders' equity.

At the beginning of the month, the Debtors had a beginning cash
balance of $1.02 million.  The Debtors had receipts from operating
and investing activities of $1.90 million and total disbursements
from financing activities of $414,662.  As a result, on October
31, the Debtor had $2.50 million cash.

A copy of the monthly operating report is available at:

                      About Fairmont General

Fairmont General Hospital Inc. and Fairmont Physicians, Inc.,
which operate a 207-bed acute-care facility in Fairmont, West
Virginia, sought Chapter 11 bankruptcy protection (Bankr. N.D.
W.Va. Case No. 13-01054) on Sept. 3, 2013, listing between
$10 million and $50 million in both assets and debts.

The fourth-largest employer in Marion County, West Virginia, filed
for bankruptcy as it looks to partner with another hospital or
health system.

The Debtors are represented by Rayford K. Adams, III, Esq., and
Casey H. Howard, Esq., at Spilman Thomas & Battle, PLLC, in
Winston-Salem, North Carolina; David R. Croft, Esq., at Spilman
Thomas & Battle, PLLC, in Wheeling, West Virginia, and Michael S.
Garrison, Esq., at Spilman Thomas & Battle, PLLC, in Morgantown,
West Virginia.  The Debtors' financial analyst is Gleason &
Associates, P.C.  The Debtors' claims and noticing agent is Epiq
Bankruptcy Solutions.

UMB Bank is represented by Nathan F. Coco, Esq., and Suzanne Jett
Trowbridge, Esq., at McDermott Will & Emery LLP.

The Committee of Unsecured Creditors is represented by Andrew
Sherman, Esq., and Boris I. Mankovetskiy, Esq., at Sills Cummis &
Gross P.C. and Kirk B. Burkley, Esq., Bernstein Burkley, P.C.
Janet Smith Holbrook, Esq., at HUDDLESTON BOLEN LLP, represents
the Committee as local counsel.

SAVIENT PHARMACEUTICALS: Incurs $2.92-Mil. Net Loss in November
Savient Pharmaceuticals, Inc., et al., on Dec., 20, 2013, filed
with the U.S. Securities and Exchange Commission their monthly
operating report for the month ended November 30, 2013.

The Debtors reported a net loss of $2.92 million on $1.65 million
net revenues.

At November 30, the Debtor reported $179.24 million in total
assets, $295.16 million in total liabilities, and -($115.91
million) total shareholders' deficit.

At the beginning of the month, the Debtors had a cash balance of
$17.32 million. They had total cash receipts of $1.80 million and
total cash disbursements of $2.40 million for the reporting
period.  Among the disbursed amounts were $193,379 in professional
fees.  Thus, at month end, the Debtors had $16.73 million cash.

A copy of the November monthly operating report is available at
the SEC at

                     About Savient Pharmaceuticals

Headquartered in Bridgewater, New Jersey, Savient Pharmaceuticals,
Inc. -- is a specialty
biopharmaceutical company focused on developing and
commercializing KRYSTEXXA(R) (pegloticase) for the treatment of
chronic gout in adult patients refractory to conventional therapy.
Savient has exclusively licensed worldwide rights to the
technology related to KRYSTEXXA and its uses from Duke University
and Mountain View Pharmaceuticals, Inc.

The Company and its affiliate, Savient Pharma Holdings, Inc.,
sought protection under Chapter 11 of the Bankruptcy Code (Bankr.
D. Del. Case No. 13-12680) on Oct. 14, 2013.

The Debtors are represented by Kenneth S. Ziman, Esq., and David
M. Turetsky, Esq., at Skadden Arps Slate Meagher & Flom LLP, in
New York; and Anthony W. Clark, Esq., at Skadden Arps Slate
Meagher & Flom LLP, in Wilmington, Delaware.  Cole, Schotz,
Meisel, Forman & Leonard P.A., also serves as the Company's
conflicts counsel, and Lazard Freres & Co. LLC serves as its
financial advisor.  GCG Inc. serves as the Debtors' claims agent.

U.S. Bank National Association, as Indenture Trustee and
Collateral Agent, is represented by Clark T. Whitmore, Esq., at
Maslon Edelman Borman & Brand, LLP, in Minneapolis, Minnesota.

The Unofficial Committee of Senior Secured Noteholders is
represented by Andrew N. Rosenberg, Esq., Elizabeth McColm, Esq.,
and Jacob A. Adlerstein, Esq., at Paul, Weiss, Rifkind, Wharton &
Garrison LLP, in New York; and Pauline K. Morgan, Esq., at Young,
Conaway, Stargatt & Taylor LLP, in Wilmington, Delaware.


Monday's edition of the TCR delivers a list of indicative prices
for bond issues that reportedly trade well below par.  Prices are
obtained by TCR editors from a variety of outside sources during
the prior week we think are reliable.  Those sources may not,
however, be complete or accurate.  The Monday Bond Pricing table
is compiled on the Friday prior to publication.  Prices reported
are not intended to reflect actual trades.  Prices for actual
trades are probably different.  Our objective is to share
information, not make markets in publicly traded securities.
Nothing in the TCR constitutes an offer or solicitation to buy or
sell any security of any kind.  It is likely that some entity
affiliated with a TCR editor holds some position in the issuers"
public debt and equity securities about which we report.

Each Tuesday edition of the TCR contains a list of companies with
insolvent balance sheets whose shares trade higher than $3 per
share in public markets.  At first glance, this list may look like
the definitive compilation of stocks that are ideal to sell short.
Don't be fooled.  Assets, for example, reported at historical cost
net of depreciation may understate the true value of a firm's
assets.  A company may establish reserves on its balance sheet for
liabilities that may never materialize.  The prices at which
equity securities trade in public market are determined by more
than a balance sheet solvency test.

A list of Meetings, Conferences and Seminars appears in each
Wednesday's edition of the TCR.  Submissions about insolvency-
related conferences are encouraged.  Send announcements to

On Thursdays, the TCR delivers a list of recently filed
Chapter 11 cases involving less than $1,000,000 in assets and
liabilities delivered to nation's bankruptcy courts.  The list
includes links to freely downloadable images of these small-dollar
petitions in Acrobat PDF format.

Each Friday's edition of the TCR includes a review about a book of
interest to troubled company professionals.  All titles are
available at your local bookstore or through  Go to order any title today.

Monthly Operating Reports are summarized in every Saturday edition
of the TCR.

The Sunday TCR delivers securitization rating news from the week

For copies of court documents filed in the District of Delaware,
please contact Vito at Parcels, Inc., at 302-658-9911.  For
bankruptcy documents filed in cases pending outside the District
of Delaware, contact Ken Troubh at Nationwide Research &
Consulting at 207/791-2852.


S U B S C R I P T I O N   I N F O R M A T I O N

Troubled Company Reporter is a daily newsletter co-published
by Bankruptcy Creditors" Service, Inc., Fairless Hills,
Pennsylvania, USA, and Beard Group, Inc., Washington, D.C., USA.
Jhonas Dampog, Marites Claro, Joy Agravante, Rousel Elaine
Tumanda, Valerie Udtuhan, Howard C. Tolentino, Carmel Paderog,
Meriam Fernandez, Ronald C. Sy, Joel Anthony G. Lopez, Cecil R.
Villacampa, Sheryl Joy P. Olano, Ivy B. Magdadaro, Carlo
Fernandez, Christopher G. Patalinghug, and Peter A. Chapman,

Copyright 2013.  All rights reserved.  ISSN: 1520-9474.

This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic
re-mailing and photocopying) is strictly prohibited without prior
written permission of the publishers.  Information contained
herein is obtained from sources believed to be reliable, but is
not guaranteed.

The TCR subscription rate is $975 for 6 months delivered via
e-mail.  Additional e-mail subscriptions for members of the same
firm for the term of the initial subscription or balance thereof
are $25 each.  For subscription information, contact Peter A.
Chapman at 215-945-7000 or Nina Novak at 202-241-8200.

                  *** End of Transmission ***